Literature DB >> 22458357

Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients.

S Petti1, A Polimeni, P B Berloco, C Scully.   

Abstract

OBJECTIVE: Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at risk of several diseases, principally attributable to immunosuppression. This global overview of SOT/HSCT-associated orofacial diseases is aimed at providing a practical instrument for the oral healthcare management of SOT/HSCT recipients.
METHODS: Literature search was made through MEDLINE. The associations between orofacial diseases and SOT/HSCT were assessed using observational studies and case series and were classified into 'association', 'no association', and 'unclear association'.
RESULTS: Lip/oral cancers, drug-induced gingival overgrowth (DIGO), infections, including hairy leukoplakia and, less frequently, post-transplantation lymphoproliferative disorders (PTLDs) and oral lichenoid lesions of graft-versus-host disease (GVHD), were associated with SOT. Lip/oral cancers, GVHD, mucositis, DIGO, infections and, less frequently, PTLDs were associated with HSCT. Associations of orofacial granulomatosis-like lesions and oral mucosa-associated lymphoid tissue-type lymphoma with SOT, and of pyogenic granuloma and hairy leukoplakia with HSCT were unclear. Periodontal disease and dental caries were not associated with SOT/HSCT. For none of the local treatments was there a strong evidence of effectiveness.
CONCLUSIONS: Solid organ transplant/HSCT recipients are at risk of orofacial diseases. Adequate management of these patients alleviates local symptoms responsible for impaired eating, helps prevent systemic and lethal complications, and helps where dental healthcare has been neglected.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22458357     DOI: 10.1111/j.1601-0825.2012.01925.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  8 in total

1.  Oral Cancer in a Patient Receiving Mercaptopurine for Ulcerative Colitis.

Authors:  Bhavik Desai; John Svirsky
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

2.  The oral microbiome - an update for oral healthcare professionals.

Authors:  M Kilian; I L C Chapple; M Hannig; P D Marsh; V Meuric; A M L Pedersen; M S Tonetti; W G Wade; E Zaura
Journal:  Br Dent J       Date:  2016-11-18       Impact factor: 1.626

3.  Impact of Immunosuppressive Drugs on Fibroblasts: An In Vitro Study.

Authors:  Gunar Wagner; Lisa Sievers; Malte Tiburcy; Wolfram Hubertus Zimmermann; Otto Kollmar; Gerhard Schmalz; Dirk Ziebolz
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

4.  The Oral Cavity State in Renal Transplant Recipients.

Authors:  Marija Gašpar; Ana Glavina; Kristina Grubišić; Ivan Sabol; Mirela Bušić; Marinka Mravak
Journal:  Acta Stomatol Croat       Date:  2015-09

Review 5.  Acquiring and maintaining a normal oral microbiome: current perspective.

Authors:  Egija Zaura; Elena A Nicu; Bastiaan P Krom; Bart J F Keijser
Journal:  Front Cell Infect Microbiol       Date:  2014-06-26       Impact factor: 5.293

6.  Croup as Unusual Presentation of Post-transplantation Lymphoproliferative Disorder after Liver Transplantation in an 18-month-old Child.

Authors:  A Keshtkari; S M Dehghani; M Haghighat; M H Imanieh; A Nasimfard; G Yousefi; H Javaherizadeh
Journal:  Int J Organ Transplant Med       Date:  2016-02-01

7.  Oral polymorphonuclear neutrophil characteristics in relation to oral health: a cross-sectional, observational clinical study.

Authors:  Patrick Rijkschroeff; Ineke D C Jansen; Fridus A van der Weijden; Bart J F Keijser; Bruno G Loos; Elena A Nicu
Journal:  Int J Oral Sci       Date:  2016-09-29       Impact factor: 6.344

8.  Head and neck cancer in living donor liver transplant recipients: Single center retrospective study.

Authors:  Nan-Chin Lin; Yao-Li Chen; Kuo-Yang Tsai
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.